GlassScriptPhysician profile
Jennifer Chang
NPI 1568631091
$4,466.21
in general payments reported to CMS, 2019-2025
36 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,666 · 2020: $51.15 · 2021: $219 · 2022: $253 · 2023: $179 · 2024: $921 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,233.42 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $707.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $617.51 | 2019-2025 | Tepezza, Evenity, Prolia |
| Dexcom, INC. | $288.60 | 2019-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $234.20 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Genzyme Corporation | $219.82 | 2019 | |
| Horizon Therapeutics Plc | $183.98 | 2019-2023 | Tepezza |
| Mannkind Corporation | $173.53 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $144.40 | 2019 | |
| Alexion Pharmaceuticals, INC. | $134.67 | 2021-2025 | Strensiq |
| Radius Health, INC. | $130.32 | 2019-2025 | Tymlos |
| Sanofi-Aventis U.S. LLC | $129.06 | 2019-2024 | |
| W. L. Gore & Associates, INC. | $128.06 | 2019 | |
| Corcept Therapeutics | $124.18 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $122.81 | 2019-2021 | |
| Insulet Corporation | $107.19 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $106.35 | 2019-2024 | Benlysta |
| Ascendis Pharma Endocrinology INC | $106.16 | 2025 | Yorvipath, Skytrofa |
| Medtronic Minimed, INC. | $89.03 | 2019 | |
| Verity Pharmaceuticals INC. | $75.62 | 2024 | Tlando |
| Abbott Laboratories | $74.41 | 2020-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $72.37 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $61.53 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Madrigal Pharmaceuticals | $60.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Bayer Healthcare Pharmaceuticals INC. | $56.77 | 2021-2025 | |
| Medtronic, INC. | $51.32 | 2024 | Minimed 780g |
| Ibsa Pharma INC. | $43.69 | 2019 | |
| Boston Scientific Corporation | $38.53 | 2024 | Emblem Mri S-Icd, Resonate El Icd Vr |
| Neurocrine Biosciences, INC. | $30.31 | 2025 | |
| Viiv Healthcare Company | $24.79 | 2024 | |
| Abbvie INC. | $22.97 | 2019 | |
| Lifescan, INC. | $21.21 | 2019 | |
| Xeris Pharmaceuticals, INC. | $18.77 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.25 | 2019 | |
| Ascensia Diabetes Care US INC. | $17.13 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $15.88 | 2019 | |
| Cequr Corporation | $14.99 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.